Guardant Health (NASDAQ:GH) Shares Down 3.5%

Shares of Guardant Health, Inc. (NASDAQ:GH) fell 3.5% on Tuesday . The stock traded as low as $24.50 and last traded at $24.50. 89,411 shares were traded during trading, a decline of 96% from the average session volume of 2,106,511 shares. The stock had previously closed at $25.38.

Analyst Ratings Changes

A number of research firms have issued reports on GH. Craig Hallum lifted their target price on Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Bank of America lifted their price target on shares of Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, July 18th. TD Cowen increased their price objective on shares of Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Stephens reaffirmed an “overweight” rating and set a $44.00 target price on shares of Guardant Health in a research note on Friday, May 24th. Finally, JPMorgan Chase & Co. increased their price target on Guardant Health from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.31.

Guardant Health Stock Performance

The company has a market capitalization of $3.10 billion, a price-to-earnings ratio of -6.39 and a beta of 1.11. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.40 and a quick ratio of 6.07. The company’s 50-day moving average price is $29.15 and its two-hundred day moving average price is $24.92.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.10). Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. The business had revenue of $177.24 million during the quarter, compared to the consensus estimate of $162.59 million. During the same period last year, the business posted ($0.67) earnings per share. The business’s revenue was up 29.2% on a year-over-year basis. On average, equities research analysts anticipate that Guardant Health, Inc. will post -3.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. International Assets Investment Management LLC bought a new stake in shares of Guardant Health during the fourth quarter valued at approximately $326,000. Truist Financial Corp acquired a new position in Guardant Health during the fourth quarter worth $258,000. Victory Capital Management Inc. lifted its stake in shares of Guardant Health by 21.2% in the fourth quarter. Victory Capital Management Inc. now owns 15,048 shares of the company’s stock valued at $407,000 after buying an additional 2,632 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Guardant Health by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,232,117 shares of the company’s stock valued at $33,329,000 after buying an additional 20,618 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of Guardant Health by 10.5% during the fourth quarter. Principal Financial Group Inc. now owns 13,045 shares of the company’s stock valued at $353,000 after buying an additional 1,240 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.